Background— The proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes independently of its enzymatic activity the degradation of the low-density lipoprotein (LDL) receptor. PCSK9 gain of function in humans leads to autosomal dominant hypercholesterolemia, whereas the absence of functional PCSK9 results in ≈7-fold lower levels of LDL cholesterol. This suggests that lowering PCSK9 may protect against atherosclerosis. Methods and Results— We investigated the role of PCSK9 in atherosclerosis in C57BL/6 wild-type (WT), apolipoprotein E–deficient, and LDL receptor–deficient mouse models. Circulating cholesterol levels, fast protein liquid chromatography profiles, aortic cholesteryl esters (CE), and plaque sizes were determined. Intima-media thicknesses were measured by ultrasound biomicroscopy. First, mice expressing null (knockout [KO]), normal (WT), or high (transgenic [Tg]) levels of PCSK9 … arabic 12 English 86
Maxime Denis, Ahmed Zaid(1-2012)

Alkaline phosphatase (ALP) enzyme level, which is routinely measured at clinical laboratories, increases in end-stage renal disease (ESRD) and hepatitis patients. This study investigated the difference in ALP level among ESRD and hepatitis patients. ALP level was measured in sera of patients suffering from ESRD, HCV and HBV infections, as well as patients suffering from comorbidity of these diseases, then the obtained values of ALP level were statistically compared to a control group. The results of three-Way ANOVA revealed that the mean of ALP level increased significantly (P-value< 0.05) in all types of diseases compared to the control group, with the highest increase in case of ESRD patients infected with Hepatitis B and C. Also, it was found that the interaction of group-gender significantly (P-value< 0.05) altered ALP level in patients suffering from HCV or HBV infections, while the interaction of group-age, gender-age, group-gender-age were found not to significantly alter it. In conclusion, ESRD patients with HBV/HCV coinfection may have a higher risk of liver-related morbidity and mortality than ESRD or HBV or HCV patients. arabic 25 English 103
HA Alemam, A Bashein(1-2020)

Abstract: Familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder of lipid metabolism, associated with elevated levels of low-density lipoprotein-cholesterol (LDLC), which can lead to premature cardiovascular disease and early death. Early diagnosis and initiation of treatment is important to prevent morbidity and mortality. Autosomal dominant hypercholesterolemia (ADH) is largely due to mutations in the low-density lipoprotein receptor gene (LDLR), the apolipoprotein B-100 gene (APOB), or the proprotein convertase subtilisin/kexin type 9 (PCSK9). In this study, genomic DNA of unrelated Libyan individuals with clinically diagnosed (FH) was analyzed by direct sequencing after dependent specific PCR primers amplification and DNA purification. That led to the identification of PCSK9 gene mutations for the first time in Libyan population which was compare to other populations. All 12 exons of PCSK9 gene and boundaries genotyped polymorphisms were sequenced, including leucine repeats coded in exon 1, by fluorescently tagged markers. We identified an allele for the rs67610340 polymorphism: an in-frame deletion, c.61_63delCTG (L8). We also identified another allele rs67610340 polymorphism: an in frame insertion c.61_63InsCTG (L10). The insertion and deletion alleles were both in exon 1 and could be associated with a risk and severity of coronary artery disease (CAD), suggesting a direct effect of PCSK9 on atherogenesis. arabic 11 English 90
Ghada Salem, Ahmed Zaid(1-2017)